| P2093 | author name string | Michael J. Abramson | |
| | John M. Weiner | |
| | Robert M. Puy | |
| P2860 | cites work | Allergen immunotherapy for asthma | Q24247724 |
| | Sublingual immunotherapy for allergic rhinitis | Q24248657 |
| | Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial | Q24555032 |
| | Measuring inconsistency in meta-analyses | Q27860655 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment | Q28276515 |
| | Quantitative synthesis in systematic reviews | Q29614894 |
| | The revised CONSORT statement for reporting randomized trials: explanation and elaboration | Q29618913 |
| | Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy | Q30468272 |
| | Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method | Q33255883 |
| | Immunotherapy in asthma: an updated systematic review | Q33760677 |
| | Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 |
| | Safety of sublingual-swallow immunotherapy in children and adults | Q33870761 |
| | Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness | Q73286236 |
| | The immunological and clinical effects of immunotherapy in patients suffering from house dust allergy | Q73295795 |
| | Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial | Q73297911 |
| | Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children | Q73303073 |
| | Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity | Q73317967 |
| | T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma | Q73486114 |
| | Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis | Q73588478 |
| | A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults | Q73668948 |
| | Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up | Q73699983 |
| | Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment | Q73823527 |
| | Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy | Q73934167 |
| | Usefulness of specific bronchial challenge in monitoring immunotherapy in occupational asthma | Q73993020 |
| | Capacity of specific immunotherapy in prevention of allergic asthma in children: the Preventive Allergy Treatment Study (PAT) | Q73993107 |
| | Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics | Q74273485 |
| | A controlled trial of immunotherapy for asthma in allergic children | Q73020915 |
| | Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy | Q73049366 |
| | Further observations on induced asthma and bronchial hyposensitization | Q73130188 |
| | Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study | Q73136562 |
| | Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial | Q73154680 |
| | Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study | Q73229297 |
| | Double-blind placebo controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens | Q73250403 |
| | Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients | Q74295467 |
| | Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers | Q74308277 |
| | Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis | Q74309230 |
| | The combined influence of immunotherapy and mite allergen reduction on bronchial hyperresponsiveness in mite-sensitive asthmatic children | Q74319045 |
| | Specific desensitization in bronchial asthma in childhood | Q74437541 |
| | Allergen-specific increase in interleukin (IL)-4 and IL-5 secretion from peripheral blood mononuclear cells during birch-pollen immunotherapy | Q74444871 |
| | Specific hyposensitization as a long term treatment of bronchial asthma | Q74514969 |
| | Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients | Q74530506 |
| | Control studies on the specificity of specific desensitization | Q75529585 |
| | Bronchial hypersensitization and hyposensitization in man | Q75745166 |
| | Prognosis of Asthma in Childhood with Special Reference to Pulmonary Function and the Value of Specific Hyposensitization | Q76489398 |
| | Activation of B-lymphocytes during pollen season. Effect of immunotherapy | Q77163343 |
| | Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy | Q77313315 |
| | Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IT) | Q77358084 |
| | Effect of immunotherapy on the production of eosinophil adhesion-inducing activity from mononuclear cells in house-dust-mite-sensitive bronchial asthma | Q77364950 |
| | Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats | Q77512630 |
| | Long-term analysis of allergen-specific T cell clones from patients with asthma treated with allergen rush immunotherapy | Q77593132 |
| | Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma | Q77661376 |
| | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study | Q77827539 |
| | Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial | Q77888858 |
| | Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy | Q78019352 |
| | Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed parietaria pollen extract over a period of three years in monosensitive patients | Q78078756 |
| | Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis | Q78256964 |
| | Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study | Q80525883 |
| | Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study | Q80541124 |
| | Control examination of the specificity of specific desensitization in asthma | Q80656019 |
| | Induced apoptosis of TH2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy | Q81378695 |
| | Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense | Q81379065 |
| | Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus | Q81913636 |
| | Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment | Q93634271 |
| | Local immunotherapy for chronic respiratory allergic pathology with allergen aerosols. II. Treatment of bronchial asthma | Q93667665 |
| | Hyposensitisation in mite asthma | Q93700563 |
| | Comparative studies of the effectiveness of specific immunotherapy in house dust mite allergy | Q44984282 |
| | Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more | Q45088211 |
| | The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study | Q45172120 |
| | The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients | Q45187312 |
| | Comparative clinical-immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma | Q45199115 |
| | Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. | Q45981112 |
| | A double blind controlled trial of Bencard house dust mite (Migen) hyposensitisation in Zambian asthmatics | Q46190770 |
| | Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study | Q46531626 |
| | Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. | Q46714664 |
| | Evaluation of near-fatal reactions to allergen immunotherapy injections | Q46875081 |
| | Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis | Q46892026 |
| | Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production | Q46961926 |
| | Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid | Q47450102 |
| | Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization | Q47702181 |
| | Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study | Q47776229 |
| | Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma | Q47783104 |
| | Specific immunotherapy downregulates peripheral blood CD4 and CD8 T-lymphocyte activation in grass pollen-sensitive asthma | Q47870649 |
| | Tolerance and short-term effect of a cluster schedule with pollen-extracts quantified in mass-units | Q47919508 |
| | Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis | Q47938843 |
| | Immunologic changes during immunotherapy in asthmatic children: increased IL-13 and allergen-specific IgG4 antibody levels | Q48020260 |
| | Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine. | Q50560405 |
| | Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. | Q50621222 |
| | Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. | Q51718271 |
| | Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. | Q52090255 |
| | Retrospective assessment of seasonal allergic symptoms: over-rating but useful. | Q52106951 |
| | The role of immunotherapy in cockroach asthma. | Q52452340 |
| | Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. | Q53551598 |
| | Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. | Q53729251 |
| | A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. | Q53854248 |
| | Photo-inactivated allergens. II. Clinical experience with house dust allergen in pulmonary function tests and in immunotherapy | Q53918747 |
| | Effect of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: changes in in vivo and in vitro responses to HDM. | Q54043746 |
| | Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. | Q54105284 |
| | A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. 1. Clinical aspects. | Q54360850 |
| | Hyposensitisation with house dust mite vaccine in bronchial asthma. | Q54960338 |
| | Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. | Q55420634 |
| | Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude | Q57117551 |
| | Immunotherapy with cat- and dog-dander extracts | Q57319721 |
| | Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen | Q61162080 |
| | Study of specific IgE and IgG4 antibodies to mite antigen in asthmatic children during immunotherapy | Q61768533 |
| | Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study | Q67235010 |
| | Treatment of allergy to house dust with pyridine-extracted alum-precipitated extracts of the house dust mite | Q67753235 |
| | The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure | Q67765791 |
| | Monitoring of various types of immunotherapy with gramineal pollens. I. Variation of clinical and biochemical parameters | Q67825362 |
| | Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies | Q67932432 |
| | Improvement of fog and exercise-induced bronchoconstriction after local and subcutaneous immunotherapy in mite asthma | Q67941704 |
| | Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy | Q67990755 |
| | Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy | Q68025918 |
| | Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one-year placebo-controlled study of immunotherapy with Cladosporium | Q68178435 |
| | Effect of immunotherapy in bronchial asthma: treatment with mite extract absorbed on tyrosine | Q68231159 |
| | Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus: a double-blind comparison with parenteral immunotherapy | Q68285809 |
| | Diagnosis and immunotherapy of mould allergy. With special reference to Cladosporium herbarum | Q68496236 |
| | Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen | Q68499158 |
| | Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season | Q68586842 |
| | A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody | Q68696676 |
| | Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects | Q68735430 |
| | Ragweed hayfever and asthma | Q68735743 |
| | Who will benefit from hyposensitization? Predictive parameters in house dust mite allergic asthmatics | Q68757457 |
| | Rapid injection therapy in children with intractable asthma: safety and technique | Q68770438 |
| | Effect of immunotherapy in bronchial asthma: treatment with extracts of house dust and mite | Q68801581 |
| | A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results | Q68876155 |
| | Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study | Q68899502 |
| | Immunotherapy for cat asthma | Q69049313 |
| | Correlation of type specific fluorescent antibodies to ragweed with symptomatology: double-blind study | Q69199784 |
| | A double blind controlled trial of house mite fortified house dust vaccine in childhood asthma | Q69342211 |
| | Rush immunotherapy with a standardized Bermuda grass pollen extract | Q69528888 |
| | Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma | Q69542749 |
| | Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study | Q69607705 |
| | Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum | Q69682074 |
| | Double blind desensitization in asthma | Q69894640 |
| | Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust | Q69936215 |
| | Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes | Q34247131 |
| | Failure of hyposensitisation in treatment of children with grass-pollen asthma. | Q34747387 |
| | Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs | Q35178388 |
| | A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. | Q36643902 |
| | Childhood asthma: application of the international view of management in Australia and New Zealand | Q37591533 |
| | Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions | Q39384234 |
| | The role of ragweed pollen in autumnal asthma | Q39436922 |
| | The clinical and immunologic specificity of immunotherapy | Q39491716 |
| | Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma | Q39515670 |
| | Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). | Q39524040 |
| | Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions | Q39580644 |
| | Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. | Q39820008 |
| | A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms | Q40527720 |
| | The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. | Q40586220 |
| | Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 |
| | Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. | Q40593688 |
| | Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial | Q40609682 |
| | Ragweed immunotherapy in adult asthma | Q40672079 |
| | Local reactions during allergen immunotherapy do not require dose adjustment | Q40738503 |
| | Oral immunotherapy in birch pollen hay fever | Q40795031 |
| | Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization | Q40816845 |
| | Orally Administered Grass Pollen | Q40832761 |
| | Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen | Q40845649 |
| | Anti-IgG Antibodies during Immunotherapy with Purified Grass Pollen Extracts | Q40845723 |
| | House dust mite hyposensitization | Q40856074 |
| | Efficacy and specificity of immunotherapy with laboratory animal allergen extracts | Q40861017 |
| | Immunotherapy in cat-induced asthma *1Double-blind trial with evaluation of bronchial responses to cat allergen and histamine | Q40879090 |
| | A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies | Q40922718 |
| | The treatment of seasonal hay fever and asthma in children. A controlled trial of pre-seasonal depot pollen therapy | Q40960047 |
| | Results of a clinical trial with a Dermatophagoides pteronyssinus tyrosine adsorbed vaccine | Q40962642 |
| | CLINICAL AND IMMUNOLOGIC EVALUATION OF A PURIFIED FRACTION OF RAGWEED POLLEN (DELTA). A DOUBLE-BLIND STUDY. | Q40968689 |
| | Study of the role of antigen dosage in the treatment of pollenosis and pollen asthma | Q41014258 |
| | Treatment of pollen hay fever and asthma with aerosols of pollen extracts | Q41027505 |
| | Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component | Q41034495 |
| | Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study | Q41040677 |
| | Effectiveness of the specific hyposensitization of children with allergoses using a peroral vaccine from house dust | Q41071036 |
| | Effect of allergen specific immunotherapy (IT) on natural killer cell activity (NK), IgE, IFN-gamma levels and clinical response in patients with allergic rhinitis and asthma | Q41152623 |
| | The future for immunotherapy | Q41165375 |
| | Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy | Q41705273 |
| | Immunotherapy in patients allergic to cat and dog dander. I. Clinical results | Q41782278 |
| | Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy | Q41955433 |
| | Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule | Q42662221 |
| | Immunotherapy with dog and cat extracts in children | Q43420428 |
| | Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy | Q43513230 |
| | Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity | Q43563812 |
| | Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen | Q43602370 |
| | Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study | Q43646876 |
| | A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma | Q43821978 |
| | Immunotherapy for mountain cedar pollinosis. A double-blind controlled study | Q44009084 |
| | Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study | Q44095490 |
| | Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites | Q44290592 |
| | Therapeutic effect and titers of the specific IgE and IgG antibodies in patients with sea squirt allergy (Hoya asthma) under a long-term hyposensitization with three sea squirt antigens | Q44295972 |
| | Specific immunotherapy with a standardized latex extract in allergic workers: A double-blind, placebo-controlled study | Q44438848 |
| | Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial | Q44545292 |
| | Effect of immunotherapy in chronic asthmatic children | Q44621172 |
| | Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study | Q44692876 |
| | Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract | Q44773540 |
| | Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma | Q44780296 |
| | Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial | Q44961338 |
| | Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment | Q69939752 |
| | Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma | Q70018361 |
| | Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement | Q70105138 |
| | Local immunotherapy with Dermatophagoides extract in asthma | Q70119879 |
| | Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract | Q70200492 |
| | Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of | Q70210011 |
| | Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy | Q70215225 |
| | Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts | Q70232271 |
| | Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody | Q70260024 |
| | A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy | Q70291997 |
| | Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis | Q70325359 |
| | A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects | Q70361437 |
| | In vitro investigations in asthmatic children undergoing hyposensitization with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen | Q70361440 |
| | A three year controlled study in children with pollinosis treated with immunotherapy | Q70366622 |
| | Comparison of Rinkel injection therapy with standard immunotherapy | Q70430240 |
| | Immunotherapy with grass pollen major allergens | Q70502797 |
| | Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma | Q70523948 |
| | A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects | Q70615175 |
| | Cellular and humoral responses following one year of hyposensitization with aqueous and tyrosine adsorbed Dermatophagoides pteronyssinus extracts | Q70622692 |
| | Side effects during immunotherapy with purified grass pollen extracts | Q70623414 |
| | Specific therapy of pollinosis. Results of desensitization with two different semi-depot allergen extracts (Allpyral and Suspal) | Q70660354 |
| | Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes | Q70741308 |
| | A double-blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients | Q70798570 |
| | Immunotherapy with the storage mite lepidoglyphus destructor | Q70798609 |
| | Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study | Q70798612 |
| | Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy | Q70843694 |
| | Local nasal immunotherapy for birch allergic rhinitis with extract in powder form | Q70952076 |
| | Efficacy of rush immunotherapy in decreasing bronchial sensitivity to inhaled antigens in perennial childhood asthma | Q71027533 |
| | Effect of immunotherapy: treatment with mite and other aeroallergens in Thai allergic patients | Q71333656 |
| | Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy | Q71501335 |
| | Rush immunotherapy with house dust extract in patients with mild extrinsic asthma | Q71524486 |
| | Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study | Q71861032 |
| | Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects | Q71943164 |
| | The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children | Q71951962 |
| | Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis | Q72059193 |
| | Depot grass-pollen injections in asthma: effect of repeated treatment on clinical response and measured bronchial sensitivity | Q72199952 |
| | Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study | Q72236154 |
| | Effects of immunotherapy on the inflammation in pollen asthma | Q72246050 |
| | Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract | Q72490899 |
| | Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively | Q72559469 |
| | The effect of immunotherapy on T-cell subsets in peripheral blood and bronchoalveolar lavage fluid in pollen-allergic patients | Q72604063 |
| | Seasonal versus perennial immunotherapy: evaluation after three years of treatment | Q72707339 |
| | Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses | Q72743177 |
| | Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial | Q72748152 |
| | Safety and efficacy of oral immunotherapy with standardized cat extract | Q72773346 |
| | Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study | Q72996277 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| | asthma | Q35869 |
| P577 | publication date | 2010-08-04 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Injection allergen immunotherapy for asthma | |